Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia

Movement Disorders

Volumn 20, Issue 9, 2005, Pages 1152-1160

  Factor, Stewart A ^a,b,c   Molho, Eric S ^a   Evans, Sharon ^a   Feustel, Paul J ^a  

^a ALBANY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Botulinum toxin type A; Botulinum toxin type B; Cervical dystonia; Secondary non response

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY EYE; DYSPHAGIA; DYSTONIA; FLU LIKE SYNDROME; GENERAL CONDITION IMPROVEMENT; HEADACHE; HEARTBURN; HUMAN; MAXIMUM PERMISSIBLE DOSE; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; TIME; TORTICOLLIS; VISUAL IMPAIRMENT; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; TORTICOLLIS;

EID: 27744461091     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20531     Document Type: Article

References (28)

1. Nutt J, Muenter MD, Aronson A, Kurland LT, Melton U. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-194.
2. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 2000;247:787-792.
3. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-1091.
4. Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord 1998;13: 486-489.
5. Muller J, Kenurder G, Wissel J, Schneider A, Voller B, Grossmann J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002;249: 842-846.
6. Camfield L, Ben-Shlomo Y, Warner TT. Impact of cervical dystonia on quality of life. Mov Disord 2002;17:838-841.
7. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 2002;72:608-614.
8. Molho ES Factor SA. Employment in cervical dystonia patients. Mov Disord 2000; 15:1043.
9. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-1072.
10. Jahanshahi M, Marsden CD. Depression in torticollis: a controlled study. Psychol Med 1988;18:925-933.
11. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998;50:1461-1463.
12. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 2004; 19:303-308.
13. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of bottflinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17: 1288-1293.
14. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246: 265-274.
15. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
16. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
17. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53:1431-1438.
18. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000;55(Suppl.):29-35.
19. Whelchel DD, Brehmer TM, Brooks PM, Darragh N, Coffield JA. Molecular targets of botulinum toxin at the mammalian neuromuscular junction. Mov Disord 2004; 1 9(Suppl.)8:7-16.
20. Consky ES, Basinki A, Belle L, Ranawaya R, Lang AE. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1990; 40(Suppl.):445.
21. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004;19(Suppl.)8:109-115.
22. Lew MF. Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. Adv Neurol 2004;94:211-215.
23. Comella CL Jankovic J, Leurgans S, Fan W, Clumara T, Dystonia Study Group. Botulinum Toxin serotype A compared to B in cervical dystonia: randomized, double-blind, parallel study. Ann Neurol 2004;56(Suppl.):25.
24. Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989;39:80-84.
25. Munchau A, Filipovic SR, Oester-Barkey A, Quinn NP, Rothwell JC, Bhatia KP. Spontaneously changing muscular activation pattern in patients with cervical dystonia. Mov Disord 2001;16:1091-1097.
26. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003;250:1263-1265.
27. Gollomp S. Clinical experiences with botulinum toxin type B (Myobloc) in the treatment of cervical dystonia: secondary resistance and electrophysiologic observations. Ann Neurol 2003; 54(Suppl.):81.
28. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.